It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Subscribe To Our Newsletter & Stay Updated
